Unicycive Therapeutics Inc (UNCY)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.89-1.27%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Unicycive Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-22.3% · beyond scale

+10% or more+5%0%−5%−10% or less

1.81 → 1.41 EPS · FY ending Dec 31, 2027 · 7 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 7; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	412,875
EPS	—	-0.322
Annual ending 2026-12-31
Revenue	—	1.52M
EPS	—	-1.247
Annual ending 2027-12-31
Revenue	—	131.36M
EPS	—	1.408

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain financial discipline and manage cash burn	Management aims to control cash burn, with operating losses near -$8.4M and cash flow around -$6.2M.	Intact	Operating loss or cash burn worsens beyond -$8.4M and -$6.2M respectively	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance clinical development programs	If clinical progress accelerates, earnings could improve from -$1.67 EPS in 2026 to positive $5.15 EPS in 2027.	Intact	Failure to meet key clinical milestones or trial delays in 2026	FDA acceptance of OLC resubmission (qualitative milestone met) FDA accepted Unicycive's OLC resubmission on Oct 22, 2026, advancing the drug toward approval and confirming no trial delays. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS improvement from losses to profitability	If clinical progress accelerates, earnings could improve from -$1.67 EPS in 2026 to positive $5.15 EPS in 2027.	Improving	EPS remains negative beyond 2027 or worsens from current guidance	Diluted EPS: $-0.06 per share FY2026-Q2; GAAP. Published target: EPS improves from -$1.67 in 2026 to positive EPS above $0 by end of 2027. Target period is not explicitly aligned with this observation. Source published Aug 12, 2026-0.06 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 89628218-77be-4b65-a97c-55f734dd5089. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$1.41

$4.62 → $1.41 · observed estimates

FY2027 revenue$0.13B

$0.29B → $0.13B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$4.62	$288,379,778	6 / 7
2026-07-25	$4.62	$288,379,778	6 / 7
2026-07-26	$4.62	$288,379,778	6 / 7
2026-07-27	$4.62	$288,379,778	6 / 7
2026-07-28	$4.62	$288,379,778	6 / 7
2026-07-29	$4.62	$288,379,778	6 / 7
2026-07-30	$4.62	$288,379,778	6 / 7
2026-07-31	$5.15	$288,379,780	8 / 9
2026-08-01	$4.62	$288,379,778	6 / 7
2026-08-02	$5.15	$288,379,780	8 / 9
2026-08-03	$4.62	$288,379,778	6 / 7
2026-08-04	$5.15	$288,379,780	8 / 9
2026-08-05	$5.15	$288,379,780	8 / 9
2026-08-06	$5.15	$288,379,780	8 / 9
2026-08-08	$4.62	$288,379,778	6 / 7
2026-08-09	$5.15	$288,379,780	8 / 9
2026-08-10	$4.62	$288,379,778	6 / 7
2026-08-12	$4.62	$288,379,778	6 / 7
2026-08-13	$5.15	$288,379,780	8 / 9
2026-08-14	$4.62	$288,379,778	6 / 7
2026-08-15	$4.62	$288,379,778	6 / 7
2026-08-16	$4.62	$288,379,778	6 / 7
2026-08-17	$4.62	$288,379,778	6 / 7
2026-08-18	$4.62	$288,379,778	6 / 7
2026-08-19	$4.62	$288,379,778	6 / 7
2026-08-20	$1.80	$150,253,556	7 / 7
2026-08-21	$1.81	$150,253,556	6 / 7
2026-08-22	$1.81	$150,253,556	6 / 7
2026-08-23	$1.81	$150,253,556	6 / 7
2026-08-24	$1.81	$150,253,556	6 / 7
2026-08-25	$1.81	$150,253,556	6 / 7
2026-08-26	$1.81	$150,253,556	6 / 7
2026-08-27	$1.81	$150,253,556	6 / 7
2026-08-28	$1.81	$150,253,556	6 / 7
2026-08-29	$1.81	$150,253,556	6 / 7
2026-08-30	$1.81	$150,253,556	6 / 7
2026-08-31	$1.81	$150,253,556	6 / 7
2026-09-01	$1.81	$150,253,556	6 / 7
2026-09-02	$1.81	$150,253,556	6 / 7
2026-09-03	$1.81	$150,253,556	6 / 7
2026-09-04	$1.81	$150,253,556	6 / 7
2026-09-05	$1.81	$150,253,556	6 / 7
2026-09-06	$1.81	$150,253,556	6 / 7
2026-09-07	$1.81	$150,253,556	6 / 7
2026-09-08	$1.81	$150,253,556	6 / 7
2026-09-09	$1.81	$150,253,556	6 / 7
2026-09-10	$1.81	$150,253,556	6 / 7
2026-09-11	$1.81	$150,253,556	6 / 7
2026-09-12	$1.81	$150,253,556	7 / 7
2026-09-13	$1.81	$150,253,556	7 / 7
2026-09-14	$1.81	$150,253,556	7 / 7
2026-09-15	$1.81	$150,253,556	7 / 7
2026-09-16	$1.81	$150,253,556	7 / 7
2026-09-17	$1.81	$150,253,556	7 / 7
2026-09-18	$1.81	$150,253,556	7 / 7
2026-09-19	$1.81	$150,253,556	7 / 7
2026-09-20	$1.81	$150,253,556	7 / 7
2026-09-21	$1.81	$150,253,556	7 / 7
2026-09-22	$1.81	$150,253,556	7 / 7
2026-09-23	$1.81	$150,253,556	7 / 7
2026-09-24	$1.81	$150,253,556	7 / 7
2026-09-25	$1.81	$150,253,556	7 / 7
2026-09-26	$1.81	$150,253,556	7 / 7
2026-09-27	$1.81	$150,253,556	7 / 7
2026-09-28	$1.81	$150,253,556	7 / 7
2026-09-29	$1.81	$150,253,556	7 / 7
2026-09-30	$1.81	$150,253,556	7 / 7
2026-10-01	$1.83	$149,503,778	7 / 7
2026-10-02	$1.83	$149,503,778	7 / 7
2026-10-03	$1.83	$149,503,778	7 / 7
2026-10-04	$1.83	$149,503,778	7 / 7
2026-10-05	$1.83	$149,503,778	7 / 7
2026-10-06	$1.83	$149,503,778	7 / 7
2026-10-07	$1.65	$143,194,250	7 / 7
2026-10-08	$1.65	$143,194,250	7 / 7
2026-10-09	$1.65	$143,194,250	7 / 7
2026-10-10	$1.65	$143,194,250	7 / 7
2026-10-11	$1.65	$143,194,250	7 / 7
2026-10-12	$1.65	$143,194,250	7 / 7
2026-10-13	$1.65	$143,194,250	7 / 7
2026-10-14	$1.65	$143,194,250	7 / 7
2026-10-15	$1.65	$143,194,250	7 / 7
2026-10-16	$1.65	$143,194,250	7 / 7
2026-10-17	$1.65	$143,194,250	7 / 7
2026-10-18	$1.65	$143,194,250	7 / 7
2026-10-19	$1.65	$143,194,250	7 / 7
2026-10-20	$1.65	$143,194,250	7 / 7
2026-10-21	$1.65	$143,194,250	7 / 7
2026-10-22	$1.64	$143,194,225	7 / 7
2026-10-23	$1.64	$143,194,225	7 / 7
2026-10-24	$1.41	$131,356,725	7 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	10	0	0
2026-06-01	10	0	0
2026-07-01	10	0	0
2026-08-01	10	0	0
2026-09-01	10	0	0
2026-10-01	10	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain financial discipline and manage cash burnDirect metric needs a verified mapping
EPS improvement from losses to profitabilityDiluted EPS: $-0.06 per share

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-60.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Unicycive Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, approval-and-launch-driven biotech thesis, not an established earnings compounder. The thesis is still in watch territory: management remains focused on OLC, but confidence in the evidence is low and recent financial performance is weak.

What's priced into Unicycive Therapeutics Inc

The available valuation evidence indicates UNCY is expensive versus peers, with optionality driving the valuation gap. The evidence does not specify exactly what approval or launch expectations the market assumes, so the expectations gap is unclear.

What the fundamentals likely do

Near term, earnings are erratic and the estimated miss risk is elevated, while recent performance has lagged its industry cohort. For the multi-year thesis, management says its resubmitted OLC application includes a new manufacturing vendor and reports cash runway into 2027, but launch preparation is still mixed and expenses have risen.

What Unicycive Therapeutics Inc hinges on

The main swing factor is whether OLC secures FDA approval and reaches launch, alongside management’s ability to build commercial readiness and manage cash. A guidance cut would be a meaningful negative; continued strength among healthcare bellwethers could support the sector backdrop, while weaker jobs data could weigh on healthcare names.